Genmab — September 2019

[E_L]

spot on indeed https://twitter.com/MM_Hub/status/1172472467471970304

[pauly]

Jeg troede alle patienter med tiden kom i 2 linie og nok også 3 linie, så meget for at tro

[Bulder]

Many pts in particularly the DRd (Maia) segment never reaches 2. line.

[Bulder]

tjek lige kursen

[Vitus]

Den drøner jo op....

[JStudsgaard]

nogen, der har opfanget noget på twitter?

[Bulder]

ligner en ofa overraskelse

[pauly]

wouw det må være ofa news

[Helge_LarsenPI-redaktør]

Vi har næsten 300 besøgende lige nu i chatten.

[Helge_LarsenPI-redaktør]

En del fra Holland.

[Helge_LarsenPI-redaktør]

Ingen ved noget åbenbart.

[E_L]

not yet https://twitter.com/AaronBosterMD/status/1172484458135588864

[pauly]

Underligt peak så

[E_L]

Novartis Phase III ASCLEPIOS trials demonstrate robust efficacy of ofatumumab in patients with relapsing multiple sclerosis

Both ASCLEPIOS I and II studies met their primary endpoints in patients with relapsing forms of MS (RMS)[1]; overall ofatumumab (OMB157), a subcutaneous,...

GlobeNewswire News Room (www.globenewswire.com)

[Legolas23]

Nogen ved noget. Ingen røg uden ild.

[E_L]

RMS patients on ofatumumab had a reduction in annualized relapse rate (ARR) by 50.5% (0.11 vs. 0.22) and 58.5% (0.10 vs. 0.25) compared to Aubagio

[Bulder]

Klart mobiltelefonen er jo opfundet

[Bulder]

Slå Ocr

[Bulder]

slår

[E_L]

Ofatumumab showed a relative risk reduction of 34.4% in 3-month confirmed disability progression (CDP†) (p=0.002) and 32.5% in 6-month CDP (p=0.012) versus Aubagio